Hepatic progenitors and strategies for liver cell therapies

R. Susick; N. Moss; H. Kubota; E. Lecluyse; G. Hamilton; T. Luntz; J. Ludlow; J. Fair; D. Gerber; K. Bergstrand; J. White; A. Bruce; O. Drury; S. Gupta; L. M. Reid

doi:10.1111/j.1749-6632.2001.tb03851.x

Hepatic progenitors and strategies for liver cell therapies

R. Susick, N. Moss, H. Kubota, E. Lecluyse, G. Hamilton, T. Luntz, J. Ludlow, J. Fair, D. Gerber, K. Bergstrand, J. White, A. Bruce, O. Drury, S. Gupta, L. M. Reid

Medicine

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Liver cell therapies, including liver cell transplantation and bioartificial livers, are being developed as alternatives to whole liver transplantation for some patients with severe liver dysfunction. Hepatic progenitors are proposed as ideal cells for use in these liver cell therapies given their ability to expand extensively, differentiate into all mature liver cells, have minimal immunogenicity, be cryopreservable, and reconstitute liver tissue when transplanted. We summarize our ongoing efforts to develop clinical programs of hepatic progenitor cell therapies with a focus on hepatic stem cell biology and strategies that have emerged in analyzing that biology.

Original language	English (US)
Pages (from-to)	398-419
Number of pages	22
Journal	Annals of the New York Academy of Sciences
Volume	944
DOIs	https://doi.org/10.1111/j.1749-6632.2001.tb03851.x
State	Published - 2001

Keywords

Hepatic progenitors
Liver
Liver cell therapies
Liver transplantation
Stem cells

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2001.tb03851.x

Cite this

@article{894a8de7116443d5b8ac967c7a76b8ee,

title = "Hepatic progenitors and strategies for liver cell therapies",

abstract = "Liver cell therapies, including liver cell transplantation and bioartificial livers, are being developed as alternatives to whole liver transplantation for some patients with severe liver dysfunction. Hepatic progenitors are proposed as ideal cells for use in these liver cell therapies given their ability to expand extensively, differentiate into all mature liver cells, have minimal immunogenicity, be cryopreservable, and reconstitute liver tissue when transplanted. We summarize our ongoing efforts to develop clinical programs of hepatic progenitor cell therapies with a focus on hepatic stem cell biology and strategies that have emerged in analyzing that biology.",

keywords = "Hepatic progenitors, Liver, Liver cell therapies, Liver transplantation, Stem cells",

author = "R. Susick and N. Moss and H. Kubota and E. Lecluyse and G. Hamilton and T. Luntz and J. Ludlow and J. Fair and D. Gerber and K. Bergstrand and J. White and A. Bruce and O. Drury and S. Gupta and Reid, {L. M.}",

year = "2001",

doi = "10.1111/j.1749-6632.2001.tb03851.x",

language = "English (US)",

volume = "944",

pages = "398--419",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Hepatic progenitors and strategies for liver cell therapies

AU - Susick, R.

AU - Moss, N.

AU - Kubota, H.

AU - Lecluyse, E.

AU - Hamilton, G.

AU - Luntz, T.

AU - Ludlow, J.

AU - Fair, J.

AU - Gerber, D.

AU - Bergstrand, K.

AU - White, J.

AU - Bruce, A.

AU - Drury, O.

AU - Gupta, S.

AU - Reid, L. M.

PY - 2001

Y1 - 2001

N2 - Liver cell therapies, including liver cell transplantation and bioartificial livers, are being developed as alternatives to whole liver transplantation for some patients with severe liver dysfunction. Hepatic progenitors are proposed as ideal cells for use in these liver cell therapies given their ability to expand extensively, differentiate into all mature liver cells, have minimal immunogenicity, be cryopreservable, and reconstitute liver tissue when transplanted. We summarize our ongoing efforts to develop clinical programs of hepatic progenitor cell therapies with a focus on hepatic stem cell biology and strategies that have emerged in analyzing that biology.

AB - Liver cell therapies, including liver cell transplantation and bioartificial livers, are being developed as alternatives to whole liver transplantation for some patients with severe liver dysfunction. Hepatic progenitors are proposed as ideal cells for use in these liver cell therapies given their ability to expand extensively, differentiate into all mature liver cells, have minimal immunogenicity, be cryopreservable, and reconstitute liver tissue when transplanted. We summarize our ongoing efforts to develop clinical programs of hepatic progenitor cell therapies with a focus on hepatic stem cell biology and strategies that have emerged in analyzing that biology.

KW - Hepatic progenitors

KW - Liver

KW - Liver cell therapies

KW - Liver transplantation

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=18244382349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244382349&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2001.tb03851.x

DO - 10.1111/j.1749-6632.2001.tb03851.x

M3 - Article

C2 - 11797689

AN - SCOPUS:18244382349

SN - 0077-8923

VL - 944

SP - 398

EP - 419

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Hepatic progenitors and strategies for liver cell therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this